49 related articles for article (PubMed ID: 22910898)
1. RECIST 1.1 versus clinico-radiological response assessment for locally advanced cervical cancer: implications on interpreting survival outcomes of future trials.
Charnalia M; Chopra S; Mulani J; Popat P; Rath S; Thomeer M; Mittal P; Gupta A; Boere I; Gupta S; Nout RA
Int J Gynecol Cancer; 2024 Apr; ():. PubMed ID: 38649234
[TBL] [Abstract][Full Text] [Related]
2. Upregulation of CRABP2 by TET1-mediated DNA hydroxymethylation attenuates mitochondrial apoptosis and promotes oxaliplatin resistance in gastric cancer.
Tang X; Liang Y; Sun G; He Q; Hou Z; Jiang X; Gao P; Qu H
Cell Death Dis; 2022 Oct; 13(10):848. PubMed ID: 36195596
[TBL] [Abstract][Full Text] [Related]
3. Some Concerns from a Radiological Point of View. Comment on Huang et al. Outcomes of Conversion Surgery for Metastatic Gastric Cancer Compared with In-Front Surgery Plus Palliative Chemotherapy or In-Front Surgery Alone.
Mazzei MA; Bagnacci G; Perrella A; Di Meglio N; Piccioni SA; Bloise F; Marrelli D; Milandri C; Mura G
J Pers Med; 2022 Jun; 12(7):. PubMed ID: 35887558
[TBL] [Abstract][Full Text] [Related]
4. The value of restaging CT following neoadjuvant chemotherapy for resectable gastric cancer. A population-based study.
Sandø AD; Fougner R; Grønbech JE; Bringeland EA
World J Surg Oncol; 2021 Jul; 19(1):212. PubMed ID: 34256790
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the RECIST 1.0 and RECIST 1.1 in patients treated with targeted agents: a pooled analysis and review.
Kim JH
Oncotarget; 2016 Mar; 7(12):13680-7. PubMed ID: 26885610
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the RECIST 1.0 and RECIST 1.1 in Non-Small Cell Lung Cancer Treated with Cytotoxic Chemotherapy.
Choi HC; Kim JH; Kim HS; Jung SG; Hwang SM; Ju SB; Yang I
J Cancer; 2015; 6(7):652-7. PubMed ID: 26078796
[TBL] [Abstract][Full Text] [Related]
7. Comparison of RECIST 1.0 and RECIST 1.1 in Patients with Metastatic Cancer: A Pooled Analysis.
Kim JH; Min SJ; Jang HJ; Cho JW; Kim SH; Kim HS
J Cancer; 2015; 6(4):387-93. PubMed ID: 25767610
[TBL] [Abstract][Full Text] [Related]
8. RECIST 1.1 compared with RECIST 1.0 in patients with advanced renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy.
Krajewski KM; Nishino M; Ramaiya NH; Choueiri TK
AJR Am J Roentgenol; 2015 Mar; 204(3):W282-8. PubMed ID: 25714313
[TBL] [Abstract][Full Text] [Related]
9. The assessment of tumor response by measuring the single largest lesion per organ in metastatic tumors: a pooled analysis of previously reported data.
Jang HJ; Cho JW; Park B; Choi HC; Kim HS; Kim JH
J Cancer; 2015; 6(2):169-76. PubMed ID: 25561982
[TBL] [Abstract][Full Text] [Related]
10. Ideal number of target lesions per organ to measure in metastatic colorectal cancer.
Kim HS; Kim JH
Oncol Lett; 2014 Oct; 8(4):1896-1900. PubMed ID: 25202433
[TBL] [Abstract][Full Text] [Related]
11. Comparison of RECIST version 1.0 and 1.1 in assessment of tumor response by computed tomography in advanced gastric cancer.
Jang GS; Kim MJ; Ha HI; Kim JH; Kim HS; Ju SB; Zang DY
Chin J Cancer Res; 2013 Dec; 25(6):689-94. PubMed ID: 24385696
[TBL] [Abstract][Full Text] [Related]
12. RECIST 1.1 and serum thyroglobulin measurements in the evaluation of responses to sorafenib in patients with radioactive iodine-refractory differentiated thyroid carcinoma.
Ruan M; Shen Y; Chen L; Li M
Oncol Lett; 2013 Aug; 6(2):480-486. PubMed ID: 24137351
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic validity of CT gastrography versus gastroscopy for primary lesions in gastric cancer: evaluating the response to chemotherapy, a retrospective analysis.
Takahashi S; Hirayama M; Kuroiwa G; Kawano Y; Takada K; Sato T; Miyanishi K; Sato Y; Takimoto R; Kobune M; Kato J
Gastric Cancer; 2013 Oct; 16(4):543-8. PubMed ID: 23187880
[TBL] [Abstract][Full Text] [Related]
14. Validity of response assessment criteria in neoadjuvant chemotherapy for gastric cancer (JCOG0507-A).
Kurokawa Y; Shibata T; Sasako M; Sano T; Tsuburaya A; Iwasaki Y; Fukuda H
Gastric Cancer; 2014; 17(3):514-21. PubMed ID: 23999869
[TBL] [Abstract][Full Text] [Related]
15. Induction chemotherapy with S-1 plus cisplatin followed by surgery for treatment of gastric cancer with peritoneal dissemination.
Okabe H; Ueda S; Obama K; Hosogi H; Sakai Y
Ann Surg Oncol; 2009 Dec; 16(12):3227-36. PubMed ID: 19777180
[TBL] [Abstract][Full Text] [Related]
16. [A case of AFP-producing gastric cancer resected after efficient S-1/CDDP combination chemotherapy].
Yoshioka M; Inoue N; Someda H; Noguchi M; Sawada M; Azuma K; Adachi A; Kuriyama D; Uose S; Nakamura T
Gan To Kagaku Ryoho; 2011 Jan; 38(1):105-8. PubMed ID: 21368468
[TBL] [Abstract][Full Text] [Related]
17. [A case of highly advanced gastric cancer with peritoneal dissemination -- a histological CR to S-1 and CDDP combination chemotherapy].
Ito Y; Kurahashi S; Ito S; Misawa K; Niwa Y; Yatabe Y; Shimizu Y
Gan To Kagaku Ryoho; 2015 Mar; 42(3):355-8. PubMed ID: 25812507
[TBL] [Abstract][Full Text] [Related]
18. Effect of RECIST revision on classification of target lesions and overall response in advanced gastric cancer patients.
Fuse N; Nagahisa-Oku E; Doi T; Sasaki T; Nomura S; Kojima T; Yano T; Tahara M; Yoshino T; Ohtsu A
Gastric Cancer; 2013 Jul; 16(3):324-8. PubMed ID: 22910898
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
